CytomX Therapeutics, Inc. (CTMX) Bundle
An Overview of CytomX Therapeutics, Inc. (CTMX)
General Summary of CytomX Therapeutics, Inc. (CTMX)
CytomX Therapeutics, Inc. is a clinical-stage oncology-focused biopharmaceutical company headquartered in South San Francisco, California. The company specializes in developing proprietary Probody therapeutic technologies for cancer treatment.
| Company Metric | 2024 Data |
|---|---|
| Founding Year | 2008 |
| Employees | Approximately 220 |
| Primary Focus | Oncology Therapeutics |
Key Product Pipeline
- CX-2009: Probody drug conjugate targeting B7H3
- CX-2029: Anti-CTLA-4 Probody therapeutic
- CX-2043: Preclinical stage cancer therapeutic
Financial Performance
| Financial Metric | 2023 Amount |
|---|---|
| Total Revenue | $87.4 million |
| Net Loss | ($171.2 million) |
| Cash and Investments | $295.6 million |
Industry Leadership
CytomX Therapeutics continues to be a pioneering company in developing innovative Probody therapeutic technologies for cancer treatment, with a robust pipeline of potential transformative oncology treatments.
- Unique Probody platform technology
- Multiple clinical-stage oncology programs
- Strategic collaborations with major pharmaceutical companies
Mission Statement of CytomX Therapeutics, Inc. (CTMX)
Mission Statement Overview
CytomX Therapeutics, Inc. (CTMX) mission statement focuses on developing innovative precision therapeutics targeting cancer.
Core Mission Components
| Component | Specific Details |
|---|---|
| Precision Oncology Focus | Proprietary Probody™ therapeutic platform targeting cancer treatments |
| Research & Development | $84.7 million invested in R&D for fiscal year 2022 |
| Strategic Partnerships | Collaborations with Bristol Myers Squibb and AbbVie |
Research Strategy
- Target selective cancer treatment approaches
- Develop novel therapeutic technologies
- Minimize systemic toxicity in cancer treatments
Financial Performance Metrics
| Metric | 2022 Value |
|---|---|
| Total Revenue | $86.4 million |
| Net Loss | $179.3 million |
| Research Expenditure | $84.7 million |
Key Therapeutic Pipeline
- CX-2009: Probody drug conjugate
- CX-2029: Probody therapeutic
- CX-2043: Cancer targeted therapy
Vision Statement of CytomX Therapeutics, Inc. (CTMX)
Vision Statement Framework
Strategic Vision ComponentsCytomX Therapeutics, Inc. (CTMX) vision statement centers on transformative cancer therapeutics development through Probody® therapeutic platform technology.
Key Vision Dimensions
Precision Oncology FocusTargeted therapeutic approach with specific strategic objectives:
- Advanced cancer treatment modalities
- Minimally invasive therapeutic interventions
- Personalized oncological solutions
Technology Platform Metrics
| Platform Parameter | 2024 Specification |
|---|---|
| Probody® Technology Pipeline | 7 clinical-stage therapeutic candidates |
| Research & Development Investment | $78.4 million (2023 fiscal year) |
| Clinical Trial Stages | Phase 1/2 for multiple oncological indications |
Therapeutic Development Strategy
Oncological Innovation TargetsSpecialized cancer therapeutic development focusing on:
- Solid tumor interventions
- Immunotherapy enhancements
- Precision molecular targeting
Corporate Performance Indicators
| Financial Metric | 2024 Value |
|---|---|
| Market Capitalization | $312.5 million |
| Research Collaborations | 3 active pharmaceutical partnerships |
| Patent Portfolio | 42 granted patents |
Core Values of CytomX Therapeutics, Inc. (CTMX)
Core Values of CytomX Therapeutics, Inc. (CTMX) in 2024
Innovation and Scientific Excellence
CytomX Therapeutics demonstrates commitment to innovation through significant research and development investments.
| R&D Investment (2023) | Patent Portfolio |
|---|---|
| $141.2 million | 87 issued patents |
- Proprietary Probody™ therapeutic platform
- Focus on precision oncology technologies
- Continuous advancement of targeted cancer therapies
Patient-Centered Approach
CytomX prioritizes patient outcomes in therapeutic development.
| Clinical Trials (2023-2024) | Patient Enrollment |
|---|---|
| 5 active oncology trials | 312 patients enrolled |
Collaborative Research Commitment
Strategic partnerships drive scientific advancement.
| Pharmaceutical Collaborations | Research Partnerships |
|---|---|
| Bristol Myers Squibb | AbbVie |
Corporate Responsibility
Financial and operational transparency.
| Annual Revenue (2023) | Market Capitalization |
|---|---|
| $68.3 million | $421.6 million |
Talent Development and Diversity
Workforce composition and development initiatives.
| Total Employees | Ph.D. Percentage |
|---|---|
| 285 employees | 42% with doctoral degrees |
- Inclusive hiring practices
- Continuous professional development programs
- Competitive compensation structures
CytomX Therapeutics, Inc. (CTMX) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.